Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of sunny skies and cool breezes enveloping the unusually quiet Pharmalot campus. Our short person is busy staring at a laptop, which is currently substituting for an education these days, and our frisky new official mascot is snoozing in a corner, having grown tired after bounding about the official campus grounds. As for us, we are quaffing cups of stimulation and invite you to join us. Meanwhile, here are a few items of interest to help you on your own journey today, such as it is. Hope you stay productive and safe. …

The World Health Organization plans to speak with the U.S. government and Gilead Sciences (GILD) about how the experimental remdesivir drug could be made more widely available to treat Covid-19 as data emerges of its effectiveness, CNBC tells us. Last Friday, the Food and Drug Administration issued an emergency use authorization, and the U.S. government will coordinate the donation and distribution of remdesivir to hospitals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The WHO should not have any input to Remdesivr allocation to the inital 1.5mm doses being made available to the US Govt, FEMA and HHS. The WHO bears blame for blocked information flow in January. They had 6 weeks knowledge of human to human spread and kept quiet.

    The head of WHO must be forced out, and ALL Chinese managers, deputies and leading scientists and researchers must be expunged. The organization is corrupt and must be cleaned out head to tail.

    Only then can the US restart funding!

Comments are closed.